[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [BUSINESS]

5 clusters · 9 sources · 48 days · First seen · Last updated

Quantum BioPharma MS therapy development

Overview

In July 2026, Quantum BioPharma announced that its proprietary multiple‑sclerosis candidate LUCID‑MS had completed Phase 1 studies in healthy volunteers with a favorable safety profile and had filed an IND with the U.S. FDA, clearing the way for patient‑focused Phase 2 trials.

By early August 2026, the company reported that a pilot imaging study conducted with Massachusetts General Hospital had reached the midpoint of patient enrollment. The PET‑based scans showed promising signals in acute MS lesions, providing a potential biomarker that could accelerate evaluation of LUCID‑MS and other remyelinating therapies.

On August 10, 2026, the FDA approved the Investigational New Drug application for LUCID-MS (Lucid-21-302), officially allowing the candidate to proceed to Phase 2 clinical development. Unlike existing therapies that focus on immune system modulation to reduce inflammation, LUCID-MS aims to provide neuroprotection by targeting the protein arginine deiminase 2 (PAD2) enzyme. This mechanism is intended to inhibit demyelination, which preclinical models suggest could prevent or even reverse myelin breakdown.

The upcoming Phase 2 study will be a randomized, double-blind, placebo-controlled trial evaluating efficacy, safety, and tolerability through clinical and radiological measures. Quantum BioPharma is currently working with a clinical research organization to support the trial and is in the process of site selection to begin patient enrollment and dosing.

On August 31, 2026, Rodman & Renshaw initiated coverage on Quantum BioPharma Ltd. with a ‘Buy’ rating and an $8.00 price target. The rating was attributed to the potential of the LUCID-MS candidate, which is being developed through the company’s subsidiary, Lucid Psycheceuticals Inc., as a patented non-immunomodulatory small molecule designed to address neurodegeneration and disability progression in progressive multiple sclerosis.

Entities

Lucid-MS · Quantum BioPharma · FDA · Quantum BioPharma Ltd. · Lucid Psycheceuticals Inc.

Timeline

  1. 11 days ago

    [BUSINESS] 2 sources
    Quantum BioPharma receives ‘Buy’ rating for Lucid-MS candidate

    Rodman & Renshaw has issued a ‘Buy’ rating and an $8.00 price target for Quantum BioPharma, citing the potential of its Lucid-MS drug candidate for treating progressive multiple sclerosis.

  2. about 1 month ago

    [BUSINESS] 4 sources
    Quantum BioPharma receives FDA clearance for Lucid-MS Phase 2 trials

    Quantum BioPharma Ltd. received FDA clearance to move its Lucid-MS candidate into Phase 2 clinical trials for the treatment of multiple sclerosis.

  3. about 1 month ago

    [HEALTH] 4 sources
    Quantum BioPharma receives FDA clearance for Lucid-MS Phase 2 trials

    Quantum BioPharma’s Lucid-MS has received FDA clearance to enter Phase 2 clinical trials, targeting neuroprotection and myelin repair in multiple sclerosis patients.

  4. about 1 month ago

    [HEALTH] 2 sources
    Quantum BioPharma reports encouraging mid‑trial results in MS imaging study

    Quantum BioPharma's MS imaging trial with Massachusetts General Hospital hits its enrollment midpoint, showing promising PET signals that support its Lucid‑MS drug targeting PAD2.

  5. about 2 months ago

    [BUSINESS] 2 sources
    Quantum BioPharma advances LUCID‑MS MS therapy to Phase 2

    Quantum BioPharma moves its LUCID‑MS multiple sclerosis therapy into Phase 2 trials after a safe Phase 1, filing an IND with the U.S. FDA and planning a partnership with Allucent.

Sources

citybizlist.com · citybuzz.co · europeanheritageawards.eu · marketersmedia.com · newmediawire.com · ohsem.me · stichtingverslaving.nl · stocktitan.net · webdisclosure.com

This summary has been updated 3 times: see revision history